Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Moderna's Coronavirus Vaccine Candidate 100% Effective at Preventing Severe COVID-19

By Cory Renauer - Nov 30, 2020 at 9:50AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company released successful clinical trial results that will support an upcoming request for Emergency Use Authorization of mRNA-1273.

On Monday morning, Moderna ( MRNA 11.79% ) released a highly encouraging primary efficacy analysis for its coronavirus vaccine candidate, mRNA-1273. The company also promised to submit a request for Emergency Use Authorization to the Food and Drug Administration by the end of the day. 

With that efficacy analysis in hand, the FDA has scheduled an independent advisory committee meeting to publicly discuss the authorization request on Dec. 17. The FDA isn't obligated to follow the advice of the independent experts it meets with, but they usually land on the same page when it comes to interpreting clinical trial data. 

Getting a vaccine injection.

Image source: Getty Images.

The primary efficacy analysis of the 30,000-patient Cove study that Moderna published today makes authorization seem likely. After 196 trial volunteers tested positive for COVID-19, investigators found 185 were among people randomized to receive a placebo. Just 11 confirmed cases of COVID-19 occurred among patients given mRNA-1273, which works out to a 94.1% efficacy rate.

It's important to note that none of the COVID-19 cases that occurred among patients vaccinated with mRNA-1273 turned severe. A similar coronavirus vaccine candidate from Pfizer ( PFE -2.96% ) and BioNTech ( BNTX 4.17% ) will be the subject of an independent advisory committee meeting with the FDA on Dec. 10. Unlike Moderna, Pfizer and BioNTech can't claim their vaccine candidate was 100% effective at preventing severe COVID-19.

About two days before Moderna's advisory committee meeting, the FDA will publish briefing documents that describe in detail any potential safety issues that could trip mRNA-1273 as it races toward the finish line. This will be the first time we see what government regulators who are privy to details that Moderna hasn't shared with the rest of us have to say about the company's vaccine candidate.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$368.51 (11.79%) $38.88
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$52.40 (-2.96%) $-1.60
BioNTech SE Stock Quote
BioNTech SE
BNTX
$362.52 (4.17%) $14.52

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
673%
 
S&P 500 Returns
142%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/30/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.